



Published in final edited form as:

Nat Med. 2008 August ; 14(8): 837–842. doi:10.1038/nm1782.

## Amyloid $\beta$ -Protein Dimers Isolated Directly from Alzheimer Brains Impair Synaptic Plasticity and Memory

Ganesh M. Shankar<sup>1,6</sup>, Shaomin Li<sup>1</sup>, Tapan H. Mehta<sup>1</sup>, Amaya Garcia-Munoz<sup>2</sup>, Nina E. Shepardson<sup>1</sup>, Imelda Smith<sup>3</sup>, Francesca M. Brett<sup>4</sup>, Michael A. Farrell<sup>4</sup>, Michael J. Rowan<sup>5</sup>, Cynthia A. Lemere<sup>1</sup>, Ciaran M. Regan<sup>2</sup>, Dominic M. Walsh<sup>3</sup>, Bernardo L. Sabatini<sup>6</sup>, and Dennis J. Selkoe<sup>1</sup>

<sup>1</sup> Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 <sup>2</sup> School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Republic of Ireland <sup>3</sup> Laboratory for Neurodegenerative Research, University College Dublin, Dublin, Republic of Ireland <sup>4</sup> Department of Pathology, Beaumont Hospital and Royal College of Surgeons Ireland, Dublin, Republic of Ireland <sup>5</sup> Trinity College Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin, Ireland <sup>6</sup> Department of Neurobiology, Harvard Medical School, Boston, MA 02115

### Abstract

Alzheimer's disease (AD) constitutes a rising threat to public health. Despite extensive research in cellular and animal models, identifying the pathogenic agent present in the human brain and showing that it confers key features of AD have not been achieved. We extracted soluble amyloid  $\beta$ -protein ( $A\beta$ ) oligomers directly from the cerebral cortex of typical AD subjects. The oligomers potently inhibited long term potentiation (LTP), enhanced long term depression (LTD), and reduced dendritic spine density in normal rodent hippocampus. Soluble  $A\beta$  from AD brain also disrupted the memory of a learned behavior in normal rats. These various effects were specifically attributable to  $A\beta$  dimers. Mechanistically, metabotropic glutamate receptors (mGluR) were required for LTD enhancement and NMDA receptors (NMDAR) for spine loss. Co-administering antibodies to the  $A\beta$  N-terminus prevented the LTP and LTD deficits, whereas antibodies to the mid-region or C-terminus were less effective. Insoluble amyloid plaque cores from AD cortex did not impair LTP unless they were first solubilized to release  $A\beta$  dimers, suggesting that plaque cores are largely inactive but sequester  $A\beta$  dimers that are synaptotoxic. We conclude that soluble  $A\beta$  oligomers extracted from AD brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species.

AD is distinguished histopathologically from other dementias by abundant extraneuronal deposits of amyloid  $\beta$ -protein ( $A\beta$ ). Numerous reports describe neuronal alterations induced by supraphysiological concentrations of synthetic  $A\beta$  peptides, by  $A\beta$  species secreted by cultured cells, or by complex mixtures of  $A\beta$  assembly forms in the brains of APP transgenic mice<sup>1–5</sup>. While these findings demonstrate that  $A\beta$  can alter synapse physiology in experimental models, the nature of the pathogenic species in the human brain and direct demonstration of its neurobiological effects are unresolved.

Aqueously soluble (Tris-buffered saline (TBS)), detergent-soluble (TBS+1% Triton) and "insoluble" (5M GuHCl) extracts were prepared by sequential centrifugation of brain homogenates from humans with various neuropathologically confirmed dementias (Supp. Table 1a). Sensitive immunoprecipitation/Western blotting (IP/WB)<sup>5,6</sup> revealed  $A\beta$  monomers and lithium dodecylsulfate (LDS)-stable dimers and trimers in all three extracts of the frontal and temporal cortices of AD subjects and an adult with Down's syndrome and AD (Fig. 1). Cortical extracts from some non-AD subjects showed modest levels of  $A\beta$  in the insoluble

(GuHCl) extracts (Fig. 1c,) but little or none in the soluble (TBS) extracts (Fig. 1a) compared to the AD cases. Notably, a subject with AD histopathology but no clinical AD (pathological AD, P-AD) showed A $\beta$  in the insoluble but not the soluble fraction. While A $\beta$  was detectable in all three sequential extracts, we chose to characterize the physiologic effects of the TBS-soluble fraction because AD dementia correlates strongly with soluble A $\beta$  levels<sup>7–9</sup>. Indeed, the profile of our extracts suggested that levels of TBS-soluble A $\beta$  correlated best with the clinical AD state (Fig. 1a vs. c). Moreover, we wished to focus on the earliest A $\beta$  assemblies: soluble oligomers that form initially from monomers.

We first asked whether soluble A $\beta$  from AD cortex (Fig. 2a; Supp. Table 1b) alters long-term potentiation (LTP) in mouse hippocampus. TBS extracts from control (Con TBS) or AD (AD TBS) cortex did not alter basal synaptic transmission or paired-pulse ratio (Supp. Figs. 1a,b), indicating that neurotransmitter release probability was unaffected<sup>10</sup>. Slices exposed to TBS vehicle (Veh) or Con TBS for 20 minutes exhibited robust LTP induction following high-frequency stimulation (HFS) ( $152.9 \pm 9.1\%$  and  $144.2 \pm 7.1\%$  of baseline fEPSP slope, respectively) (Fig. 2b). In contrast, AD TBS inhibited LTP ( $111.3 \pm 3.9\%$ ,  $P < 0.05$ ) (Fig. 2b). Immunodepleting AD TBS with an A $\beta$  antiserum (R1282) prevented the LTP inhibition (Fig. 2c), indicating that A $\beta$  was necessary. The effect of AD TBS on LTP was strongly dose-dependent (Supp. Fig. 1d). Importantly, TBS extracts prepared identically from FTD or DLB cortices did not significantly alter LTP ( $137.0 \pm 5.3\%$  and  $148.1 \pm 6.1\%$ , respectively) (Fig. 2d; Supp. Fig. 1e). Additional brain extracts from two control and three AD subjects fully replicated the above findings (Figs. 2a,d).

Long-term depression (LTD) of hippocampal synapses is induced by repetitive subthreshold stimulation<sup>11</sup>. Standard protocols for LTD induction in adult rodent hippocampus require delivery of 600–900 pulses at low frequency<sup>12,13</sup>. Accordingly, 300 pulses at 1 Hz failed to induce LTD in the presence of vehicle or Con TBS (Fig. 2e). However, AD TBS facilitated LTD induction by this weak stimulus ( $74.7 \pm 4.8\%$  of baseline for AD TBS vs.  $101.9 \pm 5.6\%$  for Con TBS,  $P < 0.05$ ) (Fig. 2e). LTD induced with AD TBS was NMDAR-independent, as the NMDAR antagonist AP-5 did not block this effect ( $68.1 \pm 4.3\%$ ) (Fig. 2f). However, both MCPG, a Group I/II mGluR antagonist ( $94.8 \pm 2.4\%$ ,  $P < 0.05$ ), and SIB1757, an mGluR5 antagonist ( $101.1 \pm 6.9\%$ ,  $P < 0.05$ ), prevented LTD facilitation by AD TBS (Fig. 2f). Whereas mGluR activation was necessary for the LTD facilitation by soluble A $\beta$ , SIB1757 did not prevent AD TBS-mediated LTP inhibition (Supp. Fig. 1f). This finding is consistent with earlier data that A $\beta$  can influence synaptic plasticity through various receptors, including NMDAR, mGluR and nicotinic acetylcholine receptors<sup>14–17</sup>.

Passive administration of monoclonal A $\beta$  antibodies has entered human testing. We found that the ability of a co-administered A $\beta$  antibody to block the above LTD facilitation correlated with its ability to IP soluble A $\beta$  from AD TBS (Supp. Fig. 2). Antibodies to the free N-terminus of A $\beta$  (3D6; 82E1) almost completely precipitated soluble A $\beta$  from AD TBS and also prevented the LTD facilitation ( $98.4 \pm 3.0\%$ ), whereas antibodies to the A $\beta$  C-termini (2G3, 21F12) weakly precipitated A $\beta$  and did not block the LTD effect ( $72.1 \pm 4.9\%$ ) (Supp. Fig. 2a,b). A $\beta$  mid-region antibodies IP'd a fraction of the A $\beta$  species in AD TBS and only partially blocked the LTD effect (Supp. Figs. 2a, c). Similarly, N-terminal but not C-terminal antibodies neutralized the LTP deficit (Supp. Fig. 2d).

To assess the effects of soluble AD cortical extracts directly on memory function, rats were trained on a step-through passive avoidance task<sup>18</sup>. At 0, 3 or 6 hr post-training, AD TBS or R1282-immunodepleted AD TBS (AD TBS-ID) (Supp. Fig. 3a) was microinjected into the lateral ventricle. AD TBS administered 3 hr post-training significantly impaired the animals' recall of the learned behavior 48 hr later (Fig. 2g). The latency to enter the dark chamber, where the rat had received a shock during training, was significantly shorter for animals injected with

AD TBS than with AD TBS-ID. Notably, AD TBS injected at 0 or 6 hr after training did not significantly alter the escape latency (Supp. Fig. 3). The 3 hr post-training time point at which AD TBS significantly impaired recall is consistent with the temporal pattern of transcriptional regulation of synapse remodelling following passive avoidance training<sup>19</sup>.

Decreased synapse density is the strongest neuropathological correlate of the degree of dementia in AD<sup>20</sup>. To determine whether soluble A $\beta$  in AD brain contributes directly to synapse loss, we quantified dendritic spine density in GFP-transfected pyramidal cells in organotypic rat hippocampal slices<sup>21</sup>. To properly reconstitute brain extracts in slice culture medium, TBS extracts underwent non-denaturing size exclusion chromatography (SEC). Pyramidal neurons in slices cultured for 10 days with plain medium (sham) or medium reconstituted with lyophilized SEC fractions of Con TBS (Con TBS-SEC) displayed similar spine densities ( $0.79 \pm 0.02$  and  $0.86 \pm 0.03$  spines/ $\mu\text{m}$ ,  $n=6/890$  and  $5/628$  cells/spines, respectively). In contrast, slice medium reconstituted with SEC fractions from AD TBS (AD TBS-SEC) caused a 47% decrease in spine density vs. Con TBS-SEC ( $0.46 \pm 0.03$  spines/ $\mu\text{m}$ ,  $P<0.05$ ;  $n=6/517$ ) (Fig. 2h; Supp. Fig. 4). MCPG did not prevent the loss of spines with AD TBS-SEC treatment ( $0.45 \pm 0.03$  spines/ $\mu\text{m}$ ;  $n=5/337$ ) (Fig. 2h). CPP, an NMDAR antagonist, did not alter spine density when applied alone but prevented the decrease observed with AD TBS-SEC ( $0.73 \pm 0.03$  and  $0.84 \pm 0.03$ , respectively;  $n=5/619$  and  $5/748$ ;  $P<0.05$  for AD TBS-SEC alone vs. AD TBS-SEC with CPP) (Fig. 2h). These findings support prior evidence that NMDAR activation is necessary for A $\beta$ -mediated spine loss<sup>16,17</sup>.

We next asked which soluble A $\beta$  species present in AD brain mediated these effects on synapse physiology. Two lines of evidence indicated that the A $\beta$ -immunoreactive species migrating at 8 kDa on LDS-PAGE gels were true A $\beta$  dimers. First, mass spectrometry of the 4 and 8 kDa bands IP'd from the GuHCl extract of AD cortex confirmed that each contained tryptic peptides of human A $\beta$  (Supp. Fig. 5b–e). Second, IP of this extract with an A $\beta$ 40-specific antibody (2G3) and WB with an A $\beta$ 42-specific antibody (21F12) revealed an A $\beta$ <sub>40/42</sub> heterodimer migrating at 8 kDa (Supp. Fig. 5a). Performing this co-IP using 21F12 for both IP and WB yielded a much stronger dimer signal, indicating that most of the 8 kDa species are A $\beta$ <sub>42/42</sub> homodimers (Supp. Fig. 5a).

Having confirmed that the 8 kDa bands detected by WB in AD brain samples (Figs. 1 and 2a) are *bona fide* A $\beta$  dimers, we used non-denaturing SEC to separate the various A $\beta$  species in AD TBS and characterized their respective effects on LTP. Most of the A $\beta$  in AD TBS eluted in the void volume ( $>60$  kDa, based on co-eluting linear polydextran standards<sup>22</sup>), but this higher MW complex dissociated into A $\beta$  monomers and dimers when denatured by LDS-PAGE (Fig. 3a, fractions 3–4). The SEC profile also showed dimers eluting at  $\sim 8$ – $16$  kDa (fractions 7–8) and monomers at  $\sim 3$ – $6$  kDa (fractions 10–11). Taken together, these results indicate that in AD cortex, soluble A $\beta$  exists in various assemblies, with the smallest native oligomer being a dimer.

To establish which soluble A $\beta$  species were responsible for the impaired synaptic plasticity, SEC fractions of AD TBS containing either higher MW complexes (AD SEC 4), native A $\beta$  dimers (AD SEC 8) or monomers (AD SEC 10) were each tested separately. Only AD SEC 8 significantly inhibited LTP ( $107.0 \pm 2.2\%$ ;  $P<0.05$  vs. Con TBS), whereas AD SEC 4, AD SEC 10, and identically prepared fractions from Con TBS were all inactive (Fig. 3b). Notably, AD SEC 4 fraction contained the highest concentration of A $\beta$  (Fig. 3a), suggesting that the specific activity of this higher MW A $\beta$  assembly is very low. To achieve a purer preparation of A $\beta$  dimers, AD TBS was IP'd with 3D6, eluted with denaturing LDS buffer and subjected to SEC (IP-SEC) (Fig. 3c). Most of the soluble A $\beta$  now eluted at the size of dimers (fractions 7–8) rather than in the void volume (Supp. Fig. 6), suggesting that elution with LDS disrupts non-covalent interactions among the higher MW A $\beta$  assemblies. LTP was significantly

inhibited by IP-SEC fractions 7–8, containing A $\beta$  dimers ( $106.6 \pm 2.4\%$ ,  $P < 0.05$ ), but not by fractions 10–11 containing monomers nor by any IP-SEC fractions from Con TBS (Fig. 3d).

Although these SEC experiments show that soluble A $\beta$  dimers inhibit LTP, it remained possible that a small molecule from human brain was bound to the A $\beta$  dimers and was required to impair LTP. To address this possibility, we generated a synthetic A $\beta_{40}$  peptide in which serine 26 was mutated to cysteine (A $\beta_{40}$ -S26C). An A $\beta$  dimer was observed upon oxidation (Fig. 3e), and this inhibited LTP nearly 20-fold more potently than did wild-type synthetic A $\beta_{40}$  (Fig. 3f). This pure, synthetic dimer cannot contain any other factors present in AD TBS, establishing that A $\beta$  dimers alone are sufficient to perturb synapse physiology.

Previous studies suggested that unlike soluble A $\beta$  levels, amyloid plaque burden correlates poorly with AD severity<sup>7,9,20</sup>. We asked whether insoluble amyloid cores isolated from AD cortex can inhibit hippocampal LTP. To isolate these detergent-resistant foci of fibrillar A $\beta$  from neuritic plaques<sup>23–25</sup>, we homogenized TBS-insoluble pellets of plaque-rich AD cortex in 2% SDS<sup>24</sup>. IP/WB of supernatants after washing in SDS buffer showed that no additional A $\beta$  was liberated by SDS or TBS from this preparation (Fig. 4a). Congo red staining of the residual pellet revealed intact amyloid cores displaying characteristic birefringence (Fig. 4b). Although resistant to disruption by many solvents, AD amyloid cores are efficiently solubilized by formic acid<sup>23,24</sup>. This treatment released A $\beta$  dimers and monomers from the washed cores (Fig. 4a). When this formic acid extract of the AD core prep was applied to hippocampal slices, LTP was inhibited ( $116.2 \pm 4.6\%$ ,  $P < 0.05$  vs. formic acid vehicle; Fig. 4c). Formic acid extracts of identically prepared fractions from control brain allowed normal LTP (Fig. 4c). Thus, amyloid cores contain A $\beta$  dimers that can impair synaptic plasticity. In contrast, addition of intact cores (Fig. 4b) to the ACSF perfusate did not affect LTP ( $139.4 \pm 7.6\%$ , Fig. 4d). Therefore, in physiologic buffer (ACSF), amyloid cores do not acutely release soluble A $\beta$  dimers to alter synaptic plasticity. IP/WB analyses revealed that A $\beta$  dimers also were not released from amyloid cores incubated in physiological buffers at 37°C for 24 hr (Supp. Fig. 7), suggesting that highly insoluble A $\beta$  aggregates such as amyloid plaque cores represent dimer-rich structures that do not readily dissociate.

Here, we show that soluble A $\beta$  isolated directly from AD brains potently and consistently induces several AD-like phenotypes in normal adult rodents: it decreases dendritic spine density, inhibits LTP and facilitates LTD in hippocampus, and interferes with the memory of a learned behavior. We used non-denaturing gel filtration coupled with IP/WB and subsequent immunodepletion or neutralization with epitope-specific A $\beta$  antibodies to ascribe the pathogenic effects to soluble A $\beta$  oligomers, principally dimers.

Our findings support the emerging concept that the effects of A $\beta$  in AD center initially on subtly altered synapse function. Neither A $\beta$  monomers nor insoluble amyloid plaque cores significantly altered synaptic plasticity. This does not mean that insoluble amyloid plaques have no pathogenic role; their invariant accumulation may signify that they serve as relatively inert reservoirs of small bioactive oligomers, and they may disassemble more readily in the presence of lipids<sup>26</sup>. That plaque cores may release locally active A $\beta$  species *in vivo* is suggested by a penumbra of synapse loss around cores in APP transgenic mice<sup>27</sup>.

Our examination of soluble dimers obtained from AD brain is partially consistent with findings using synthetic<sup>2</sup> or cell-derived<sup>5,28</sup> A $\beta$  oligomers. However, there are unresolved differences regarding the precise biochemical nature of the synaptotoxic species found in these various systems. For example, we did not detect (Fig. 1 and Supp. Fig. 6) a soluble, SDS-stable dodecamer of A $\beta$  in human cortical extracts such as the A $\beta^{*56}$  species observed in brain extracts from certain APP transgenic mice<sup>29</sup>. Soluble A $\beta$  complexes from AD cortex eluted in the void volume (>70 kDa) upon non-denaturing SEC, but these dissociated into dimers and

monomers upon LDS-PAGE. Some AD and aged control CSF samples that contain soluble A $\beta$  dimers were recently shown to impair LTP<sup>30</sup>, a finding consistent with our data. However, the invariant detection of dimers in the soluble fraction of AD cortex and their multiple synaptic effects strongly suggest that cortical dimers contribute directly to synapse dysfunction in AD patients, whereas any additional effects of CSF dimers in the minority of AD subjects who have them<sup>30</sup> remain to be determined.

Mechanistically, we show that soluble A $\beta$  dimers from AD cortex induce their effects by perturbing glutamatergic synaptic transmission. Although we find that mGluRs are required for the induction of LTD while NMDARs are needed for spine loss, these receptors are unlikely to be the sole effector targets of soluble A $\beta$  oligomers. A $\beta$  extracted from human brain can now serve as the most pathophysiologically relevant material for further pathway analysis and for preclinical validation of agents designed to neutralize A $\beta$  aggregates. Our findings fulfill an essential requirement for establishing disease causation in AD.

## METHODS

### Human brain sample preparation

Brain specimens from deceased human subjects were collected at autopsy following informed consent from the next of kin under protocols approved by the Partners Human Research Committee at Brigham and Women's Hospital and the ERC/IRB committee at Beaumont Hospital in Dublin, Ireland. Each subject's clinical and neuropathological diagnoses are provided in Supp. Tables 1. Frozen human temporal or frontal cortices containing white and grey matter were weighed. Freshly prepared, ice cold Tris-buffered saline (TBS) consisting of 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 was added to the frozen cortex at 4:1 (TBS volume:brain wet wt) and homogenized with 25 strokes at a setting of 10 on a mechanical Dounce homogenizer. The homogenate was spun at 175,000 g in a TLA100.2 rotor on a Beckman TL 100. The supernate (called TBS extract) was aliquoted and stored at  $-80^{\circ}\text{C}$ , and the pellet was re-homogenized (4:1 v:w) in TBS + 1% Triton X-100 and spun as above. The resultant sup (called TBS-TX extract) was aliquoted and stored at  $-80^{\circ}\text{C}$ , and the pellet was re-homogenized in TBS + 5 M guanidine HCl, pH 8.0, and incubated on a Nutator for 12–16 hr at RT; the resultant sup (GuHCl extract) was aliquoted and stored at  $-80^{\circ}\text{C}$ .

### Size exclusion chromatography (SEC)

One mL aliquots of the TBS-soluble AD brain extract were injected onto a Superdex 75 (10/30HR) column (Amersham Biosciences, Piscataway, NJ) and eluted at a flow rate of 1 ml/min into 1 ml SEC fractions using 50 mM ammonium acetate, pH 8.5. 750  $\mu\text{L}$  were removed and stored at  $-80^{\circ}\text{C}$ . The remaining 250  $\mu\text{L}$  were lyophilized, reconstituted in 15  $\mu\text{L}$  of 2X lithium dodecyl sulfate (LDS) sample buffer, heated at  $70^{\circ}\text{C}$  for 5 min and electrophoresed on a 26-well 4–12% bis-tris gel using MES running buffer (Invitrogen). Proteins were transferred to 0.2  $\mu\text{m}$  nitrocellulose and Western blotted (WB) for A $\beta$  with 1  $\mu\text{g}/\text{ml}$  2G3 + 21F12 (gifts of Elan, plc) using the LiCor Odyssey Infrared Imaging System. SEC fractions containing higher order A $\beta$  assemblies, LDS-stable A $\beta$  dimers or A $\beta$  monomers were pooled separately prior to lyophilizing into 450  $\mu\text{L}$  aliquots.

### Immunoprecipitation (IP)/WB analysis of A $\beta$ in human brain extracts

We used an IP/WB protocol described previously<sup>6</sup> to detect A $\beta$  in the TBS, TBS-TX and GuHCl extracts. TBS extracts were IP'ed directly with either polyclonal A $\beta$  antiserum R1282 (1:50) plus Protein A sepharose (PAS; Sigma) or monoclonal A $\beta$  antibodies 3D6 (3  $\mu\text{g}/\text{mL}$ ) or 2G3 + 21F12 (each at 3  $\mu\text{g}/\text{mL}$ ) (gifts of Elan, plc) plus Protein G agarose (PGA; Roche) and PAS. GuHCl extracts were diluted 1:40 in DMEM and then IP'ed with R1282 (at 1:50)

and PAS or else with 2 µg/mL 266+2G3+21F12 and PGA and PAS. Silver staining used the SilverQuest kit fast protocol (Invitrogen).

### Hippocampal slice electrophysiology recording

The Harvard Medical School Standing Committee on Animals approved all experiments involving vertebrate animals used for electrophysiology and dendritic spine analysis. Standard field excitatory postsynaptic potentials (fEPSP) in the CA1 region of the mouse hippocampus were recorded. A unipolar stimulating electrode (World Precision Instruments, Sarasota, FL) was placed in the Schaffer collaterals of CA3 neurons to deliver test and conditioning stimuli. A borosilicate glass recording electrode filled with ACSF was positioned in stratum radiatum of CA1, 200–300 µm from the stimulating electrode. fEPSPs in CA1 were induced by 2 test stimuli at 0.05 Hz with an intensity that elicited a fEPSP amplitude 40~50% of maximum. Once a stable test response was attained for at least 30–60 min, experimental treatments were added to the 9.5 mL ACSF perfusate, and a baseline was recorded for an additional 20 min. These treatments included: 500 µL TBS extract, 500 µL TBS vehicle, 50 µM AP-V, 500 µM (R/S)-MCPG (Tocris) or 3 µM SIB1757. Lyophilized 450 µL aliquots of SEC fractions of GuHCl extracts described above were reconstituted in 500 µL ACSF and added to the slice perfusates. To induce LTP, we applied two consecutive trains (1 s) of stimuli at 100 Hz separated by 20 s, a protocol that induced LTP lasting approximately 1.5 hr in wt mice of this genetic background. To induce LTD, 300 pulses were delivered at 1 Hz. The field potentials were amplified 100x using an Axon Instruments 200B amplifier and digitized with Digidata 1322A. The data were sampled at 10 kHz and filtered at 2 kHz. Traces were obtained by pClamp 9.2 and analyzed using the Clampfit 9.2 program. LTP and LTD values reported throughout were measured at 60 min after the conditioning stimulus unless stated otherwise. Paired-pulse responses were monitored at 50 ms inter-stimulus intervals. The facilitation ratio was calculated as fEPSP2 slope/fEPSP1 slope. One-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test were used to determine statistical significance.

### Passive Avoidance Conditioning

Passive avoidance training was performed as described previously<sup>18</sup> (see Supplemental Methods). Wistar rats were administered AD TBS or AD TBS immunodepleted with R1282 at 0, 3, or 6 hr post-training. Recall of the passive avoidance conditioning was evaluated 24 and 48 hr post-training by recording the latency to enter the dark chamber, with a criterion time of 300 s. Data from the passive avoidance studies were analyzed by ANOVA followed by the Bonferroni post hoc test.

### Dendritic spine density analysis

The apical dendrites of pyramidal cells in organotypic hippocampal slices were prepared, treated, imaged and analyzed as described<sup>17</sup> (see Supplemental Methods). Slices were treated for 10 d with AD TBS-SEC or Con TBS-SEC. Pharmacologic treatments were performed with 20 µM D-CPP or 500 µM (R/S)-MCPG in the presence or absence of AD TBS-SEC for 10 d.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments


Mass spectrometry was performed by the Taplin Biological Mass Spectrometry Facility (S. Gygi). We thank X. Sun and W. Qiu for performing ELISA. We thank members of the Selkoe laboratory for helpful comments. G.M.S. recognizes L. Gurumani for support and encouragement. This work was supported by National Institute on Aging grant AG R01 027443 (D.J.S., G.M.S., S.L., T.H.M., N.E.S.), Science Foundation Ireland grant 03/IN3/B403C (C.M.R., A.G-M.), and Wellcome Trust grant 067660 (D.M.W., I.S.).

## References

1. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. *Proc Natl Acad Sci U S A* 1994;91:12243–7. [PubMed: 7991613]
2. Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* 1998;95:6448–53. [PubMed: 9600986]
3. Mucke L, et al. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci* 2000;20:4050–8. [PubMed: 10818140]
4. Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 2000;408:982–5. [PubMed: 11140686]
5. Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 2002;416:535–9. [PubMed: 11932745]
6. Walsh DM, Tseng BP, Rydel RE, Podlisky MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry* 2000;39:10831–9. [PubMed: 10978169]
7. McLean CA, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol* 1999;46:860–6. [PubMed: 10589538]
8. Kuo YM, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. *J Biol Chem* 1996;271:4077–81. [PubMed: 8626743]
9. Lue LF, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol* 1999;155:853–62. [PubMed: 10487842]
10. Schulz PE, Cook EP, Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. *J Neurosci* 1994;14:5325–37. [PubMed: 7916043]
11. Kemp N, Bashir ZI. Long-term depression: a cascade of induction and expression mechanisms. *Prog Neurobiol* 2001;65:339–65. [PubMed: 11527572]
12. Dudek SM, Bear MF. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. *Proc Natl Acad Sci U S A* 1992;89:4363–7. [PubMed: 1350090]
13. Mulkey RM, Malenka RC. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. *Neuron* 1992;9:967–75. [PubMed: 1419003]
14. Tyszkiewicz JP, Yan Z. beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. *J Neurophysiol* 2005;93:3102–11. [PubMed: 15659527]
15. Hsieh H, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron* 2006;52:831–43. [PubMed: 17145504]
16. Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. *J Neurosci* 2007;27:796–807. [PubMed: 17251419]
17. Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J Neurosci* 2007;27:2866–75. [PubMed: 17360908]
18. Fox GB, O'Connell AW, Murphy KJ, Regan CM. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. *J Neurochem* 1995;65:2796–9. [PubMed: 7595580]
19. O'Sullivan NC, et al. Temporal change in gene expression in the rat dentate gyrus following passive avoidance learning. *J Neurochem* 2007;101:1085–98. [PubMed: 17298388]
20. Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann Neurol* 1991;30:572–80. [PubMed: 1789684]
21. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. *Nat Neurosci* 2005;8:1727–34. [PubMed: 16286931]

22. Walsh DM, et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. *J Neurosci* 2005;25:2455–62. [PubMed: 15758153]
23. Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* 1985;82:4245–9. [PubMed: 3159021]
24. Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. *J Neurochem* 1986;46:1820–34. [PubMed: 3517233]
25. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. *J Neurochem* 1993;61:1916–26. [PubMed: 8229002]
26. Martins IC, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. *Embo J* 2008;27:224–33. [PubMed: 18059472]
27. Spires TL, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. *J Neurosci* 2005;25:7278–87. [PubMed: 16079410]
28. Cleary JP, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* 2005;8:79–84. [PubMed: 15608634]
29. Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 2006;440:352–7. [PubMed: 16541076]
30. Klyubin I, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. *J Neurosci* 2008;28:4231–7. [PubMed: 18417702]






**Figure 1.**


Monomeric and oligomeric A $\beta$  is detected in brain extracts of humans with clinically and neuropathologically typical late-onset AD. IP/WB analysis (see Methods) was performed on supernatants of the soluble (**a**, TBS), membrane-associated (**b**, TBS-TX100) and insoluble (**c**, GuHCl) sequential extracts of frontal (F) and temporal (T) cortex homogenates from various individuals diagnosed with different forms of dementia (see Supp. Table 1). Samples were IP'ed with polyclonal A $\beta$  antibody R1282 and blotted with monoclonals 2G3 (A $\beta$ <sub>40</sub>) + 21F12 (A $\beta$ <sub>42</sub>). Subject key: DS, Down's syndrome with AD; DLB, dementia with Lewy bodies; PCD, paraneoplastic cerebellar degeneration; AD, Alzheimer's disease; MID, multi-infarct

dementia; P-AD, “pathological AD” (i.e., scattered amyloid plaques without a history of clinical AD); FTD, frontotemporal dementia. See Supp. Table 1a for further information.




**Figure 2.** Soluble A $\beta$  extracted from AD brain alters hippocampal synapse physiology and learned behavior. **(a)** IP/WB of the TBS brain extracts used to study LTP. Clinical and neuropathological diagnoses for each of these seven cases are provided in Supp. Table 1b. **(b)** Summary data of LTP induction following two 100 Hz stimuli (HFS, arrow) of slices treated with 500  $\mu\text{L}$  each of TBS vehicle (Veh;  $n=8$  slices), Con 1 TBS extract (Con TBS;  $n=6$ ) or AD 4 TBS extract (AD TBS;  $n=8$ ). Insets show average baseline (light) and post-HFS (dark) fEPSP traces; calibration bars 5 msec/0.2 mV. **(c)** LTP is induced normally in hippocampal slices treated with 500  $\mu\text{L}$  of immunodepleted AD TBS (AD TBS-ID). The summary LTP data for Con TBS (blue,  $n=6$  slices) and AD TBS (red,  $n=8$  slices) from Fig. 2b are represented as

horizontal bars depicting means  $\pm$  SEMs of fEPSP slopes at ~50–60 min post-HFS. *Inset*: Two sequential IP's (R1282) of AD TBS blotted with 2G3+21F12. **(d)** Summary LTP data (means  $\pm$  SEMs) for 3 different control subjects (Con 1,  $n=6$ ; Con 2,  $n=6$ ; Con 3,  $n=6$ ), 4 AD subjects (AD 4  $n=8$ ; AD 5,  $n=5$ ; AD 6,  $n=6$ ; AD 7,  $n=6$ ), 1 FTD subject ( $n=5$ ) and 1 DLB subject ( $n=6$ ). For comparison, LTP data from Fig. 2b for Veh are represented by the grey horizontal bar. \* $P<0.05$  compared with Veh. **(e)** Summary LTD data for slices treated with 500  $\mu$ L Con TBS (blue,  $n=7$ ) or AD TBS (red,  $n=8$ ) for 10 min prior to a weak stimulation protocol of 300 pulses at 1 Hz, indicated by the small grey bar. Calibration bars 5 msec/0.2 mV. **(f)** Summary LTD data for co-administration of AD TBS with either 50  $\mu$ M AP-V (black,  $n=8$ ), 500  $\mu$ M (R/S)-MCPG (green,  $n=7$ ) or 3  $\mu$ M SIB1757 (orange,  $n=6$ ). For comparison, LTD data (means  $\pm$  SEM) for Con TBS (blue) and AD TBS (red) are shown as horizontal bars. **(g)** Cumulative probability distribution representing escape latency for animals receiving AD TBS (red) or AD TBS-ID (black) at 48 hr after training. Animals receiving AD TBS had a significantly shorter mean escape latency than animals receiving AD TBS-ID ( $174 \pm 31.7$  sec and  $255 \pm 22.8$  sec, respectively;  $P<0.05$ ;  $n=11$  and 10 rats). **(h)** Summary spine density data for pyramidal cells exposed to SEC-enriched TBS extract from AD brain (AD TBS-SEC) or from Con brain (Con TBS-SEC) and also for slices treated with 500  $\mu$ M MCPG or 20  $\mu$ M CPP in the presence or absence of AD TBS-SEC. \*,# $P<0.05$  vs. Con TBS-SEC and vs. AD TBS-SEC, respectively.

**Figure 3.**

Soluble dimers are the smallest A $\beta$  assembly form in human brain to acutely perturb synapse physiology. (a) TBS extracts of AD (top panel) and control (bottom panel) brains were subjected to non-denaturing SEC. SEC fractions were lyophilized and WB'd with 2G3+21F12; molecular weights (in kDa) on left. Note that A $\beta$  monomer and dimer in the AD TBS extract is recovered from material that elutes at the end of the void volume (fractions 3/4). Control (Con) brain extracts were devoid of A $\beta$ . (b) Summary LTP data (means  $\pm$  SEMs) for slices treated with SEC fractions from AD or Con TBS extracts ( $n=6$  slices for all samples), as characterized in Fig. 3a. (c) Representative WB (2G3+21F12) of IP-SEC fractionation of AD TBS and Con TBS. TBS extracts (500  $\mu$ L) were immunoprecipitated with 3D6 (3  $\mu$ g/mL), eluted with sample buffer and subjected to SEC. Dimer-enriched (fractions 7–8) and monomer-enriched (fractions 10–11) IP-SEC fractions were separately pooled, as were corresponding fractions from Con TBS. (d) Summary LTP data (means  $\pm$  SEMs) for slices treated with IP-SEC fractions of AD and control brain TBS extracts, as characterized in Fig. 3c (Con fractions 10–11,  $n=5$ ; AD fractions 10–11,  $n=5$ ; Con fractions 7–8,  $n=7$ ; AD fractions 7–8,  $n=7$ ). (e) Mutant A $\beta_{40}$ -S26C forms dimers under oxidizing conditions (ox), which can be reduced to monomers by treating with  $\beta$ -ME (red). Silver stain was performed with 100 ng wildtype A $\beta_{40}$  (wt) peptide or the mutant peptide (f) Summary LTP data (means  $\pm$  SEMs) for slices treated with 5, 50, or 100 nM of either wt A $\beta_{40}$  (black) or oxidized A $\beta_{40}$ -S26C (red) reveals that the oxidized A $\beta_{40}$ -S26C dimer inhibits LTP with much greater potency (100 nM A $\beta_{40}$ -S26C,  $n=4$ ;  $n=5$  for all other treatments). The vehicle controls (plotted at 0 nM) were 50 mM ammonium acetate ( $n=4$ ) for the S26C peptide and 0.1% ammonium hydroxide ( $n=4$ ) for wt peptide.



**Figure 4.** Insoluble amyloid cores contain A $\beta$  dimers with synaptotoxic potential but are not readily released. **(a)** IP/WB of sequential extracts of the TBS-insoluble pellet prepared from 100 mg of a plaque-rich AD brain (case AD 5 from Fig. 2a) (see Methods). The final TBS washes reveal that no additional soluble A $\beta$  can be extracted from the pellet after 4 sequential SDS washes. The remaining core-rich pellet was then incubated in formic acid (FA core extract) and analyzed by IP/WB, revealing that the insoluble cores contain A $\beta$  monomers and dimers (far right lane). **(b)** Core preps following the final TBS wash as in Fig. 4a were stained with 0.2% Congo red and visualized by brightfield (left) and polarization (right) microscopy. Isolated amyloid cores display characteristic birefringence with Congo red (red arrowheads).

Material prepared similarly from Con 3 (Fig. 2a) did not contain any such structures. Scale bar = 5  $\mu\text{m}$ . **(c)** Cores prepared as in Figs. 4a, b were extracted with 88% formic acid and neutralized with NaOH. Summary LTP data for slices treated with just FA/NaOH vehicle (FA Veh,  $n=5$ ), or with FA/NaOH core extracts from AD (AD core FA extract,  $n=7$ ) or control (Con core FA extract,  $n=5$ ) brains. Calibration bars, 5 msec/0.2 mV. **(d)** Summary LTP data for slices exposed to intact core preps isolated as in Fig. 4a, b from 100 mg AD cortex (AD core prep,  $n=5$ ) or Con cortex (Con core prep,  $n=5$ ). Calibration bars, 5 msec/0.3 mV.